News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
《大行》富瑞升石藥集團(01093.HK)目標價至7.2元 維持「跑輸大市」評級
富瑞發表研究報告，指石藥集團(01093.HK)去年業績仍面臨壓力，全年收入按年跌10%至260億元人民幣(下同)，遜預期。雖然管理層預期成品藥業務今年可恢復正增長，但市場關注潛在帶量採購(VBP)風險，包括鹽酸伊立替康脂質體注射液可能被納入全國VBP。富瑞認為，管理階層預期帶量採購的不利因素將在今年持續。雖然業務拓展(BD)是關鍵，但市場仍將股價押注預付款...
Reset
Send
The window will close in 5 seconds
《大行》富瑞升石藥集團(01093.HK)目標價至7.2元 維持「跑輸大市」評級
Close
Recommend
6
Positive
13
Negative
6
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

富瑞發表研究報告，指石藥集團(01093.HK)  +0.090 (+0.936%)    Short selling $314.42M; Ratio 92.374%   去年業績仍面臨壓力，全年收入按年跌10%至260億元人民幣(下同)，遜預期。雖然管理層預期成品藥業務今年可恢復正增長，但市場關注潛在帶量採購(VBP)風險，包括鹽酸伊立替康脂質體注射液可能被納入全國VBP。

富瑞認為，管理階層預期帶量採購的不利因素將在今年持續。雖然業務拓展(BD)是關鍵，但市場仍將股價押注預付款憧憬，隨着預期上調，失望的風險正在上升。

該行維持石藥「跑輸大市」評級，但目標價由5.9元升至7.2元。(hc/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.